UPCOMING EVENTS

Baylor College of Medicine in Houston Enrolling Eligible Women in Study for Patients With Hormone Receptor-Positive Advanced Breast Cancer

Posted 6-02-2014

Baylor College of Medicine in Houston is enrolling eligible women in FALCON, a Phase III study which will involve approximately 600 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy.

The study taking place at Baylor College of Medicine is part of a global clinical trial through MedImmune Specialty Care Division of AstraZeneca.

Baylor College of Medicine, along with more than 100 other global clinical trial sites, are enrolling patients that are eligible to participate based on the following requirements:

  • Female
  • Postmenopausal
  • Have hormone receptor-positive locally advanced or metastatic breast cancer
  • Have not received prior hormonal therapy

For more information about the trial (NCT01602380), please contact 713-798-4951 at Baylor College of Medicine, or visit astrazenecaclinicaltrials.com.

View the Clinical Trial Flyer

 

Bookmark and Share

 

Website designed and developed by Success Designs LLC